Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thalidomide in multiple myeloma: current status and future prospects.

× No keyword cloud information.

9 in total

Review 1. Management of thalidomide toxicity.

Authors: Irene M Ghobrial; S Vincent Rajkumar
Journal: J Support Oncol Date: 2003 Sep-Oct

2. Innovative strategies in lymphoma therapy.

Authors: Ulrich Jäger
Journal: Wien Klin Wochenschr Date: 2003-08-14 Impact factor: 1.704

3. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Authors: Jae-Cheol Jo; Byung Woog Kang; Sun Jin Sym; Sung Sook Lee; Geundoo Jang; Shin Kim; Dae Ho Lee; Sang-We Kim; Jung Shin Lee; Cheolwon Suh
Journal: Invest New Drugs Date: 2009-10-13 Impact factor: 3.850

4. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Authors: Britta Auel; Hartmut Goldschmidt; Thomas Geer; Thomas M Moehler; Uwe Platzbecker; Ralph Naumann; Igor Blau; Mathias Hänel; Wolfgang Knauf; Holger Nückel; Hans-Jürgen Salwender; Christof Scheid; Katja Weisel; Marcus Gorschlüter; Axel Glasmacher; Ingo G H Schmidt-Wolf
Journal: Indian J Hematol Blood Transfus Date: 2011-08-18 Impact factor: 0.900

5. Thalidomide-induced severe neutropenia during treatment of multiple myeloma.

Authors: Yutaka Hattori; Tsunayuki Kakimoto; Shinichiro Okamoto; Norihide Sato; Yasuo Ikeda
Journal: Int J Hematol Date: 2004-04 Impact factor: 2.490

6. Bortezomib: the evidence of its clinical impact in multiple myeloma.

Authors: Simon Lancaster
Journal: Core Evid Date: 2006-06-30

Review 7. Evolving treatment strategies for myeloma.

Authors: G J Morgan; F E Davies
Journal: Br J Cancer Date: 2005-01-31 Impact factor: 7.640

8. Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma.

Authors: Satkirin K Khalsa; Catherine C Roberts; Michael S Underhill
Journal: Radiol Case Rep Date: 2015-12-07

9. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.

Authors: I Hus; A Dmoszynska; J Manko; M Hus; D Jawniak; M Soroka-Wojtaszko; A Hellmann; H Ciepluch; A Skotnicki; T Wolska-Smolen; K Sulek; T Robak; L Konopka; J Kloczko
Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640

9 in total